Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO

On Monday, in its earnings release, Myriad Genetics Inc. (NASDAQ:MYGN) said Unitedhealth Group Inc’s (NYSE:UNH) UnitedHealthcare will stop covering multi-gene panel pharmacogenetic testing, including Myriad Genetics’ GeneSight test, for its commercial, individual exchange, and certain managed…